|
22 Mar 2019 |
GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in patients with relapsed/refractory multiple myeloma
|
|
21 Mar 2019 |
Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta
|
|
21 Mar 2019 |
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
|
|
21 Mar 2019 |
Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody
|
|
21 Mar 2019 |
BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors
|
|
21 Mar 2019 |
Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer
|
|
20 Mar 2019 |
I-Mab Biopharma Announces Dosing of First Subject in Phase 1 Clinical Trial of Anti-GM-CSF Monoclonal Antibody TJM2 in the United States
|
|
20 Mar 2019 |
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
|
|
20 Mar 2019 |
I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma
|
|
20 Mar 2019 |
Tiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH
|
|
20 Mar 2019 |
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases
|
|
19 Mar 2019 |
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody in the U.S.
|
|
19 Mar 2019 |
Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis
|
|
19 Mar 2019 |
FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
|
|
17 Mar 2019 |
Praluent (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
|
|
15 Mar 2019 |
Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers
|
|
15 Mar 2019 |
European Commission approves Roche’s MabThera (rituximab) for a rare autoimmune disease
|
|
14 Mar 2019 |
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
|
|
14 Mar 2019 |
Chugai’s Hemlibra Receives Approval for Severe Hemophilia A Without Factor VIII Inhibitors from the European Commission
|
|
14 Mar 2019 |
BioArctic Announces Start of Phase 1 Study of ABBV-0805 for Parkinson's Disease
|
|
13 Mar 2019 |
Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
|
|
13 Mar 2019 |
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
|
|
13 Mar 2019 |
Janssen Submits Application to U.S. FDA Seeking Approval of DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
|
|
13 Mar 2019 |
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA®
|
|
13 Mar 2019 |
U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1
|
